 |
|
|
October 2008 Issue |
Volume 13, Number 10 |
|
|
|
Lead Stories for this Issue |
|
|
|
New Weapons Against Blood Clots: The Novel Antithrombotic Pipeline
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
The Many Targets of New Platelet Inhibitors
Go to This Issue >>
|
|
|
|
|
September 2008 Issue |
Volume 13, Number 9 |
|
|
|
Lead Stories for this Issue |
|
|
|
Running Late: FDA Review Timelines Lengthen For New Product Applications
On Time In Hard Times: FDA's User Fee Goal Performance
FDA's Near (And Far) Misses: Applications With Overdue Review Decisions
Go to This Issue >>
|
|
|
|
|
August 2008 Issue |
Volume 13, Number 8 |
|
|
|
Lead Stories for this Issue |
|
|
|
Tracking Troubled NDAs: New FDA Regs Mean Less Clarity For Investors
J&J’s Doribax Is Subject Of FDA’s First "Complete Response" To An NDA
FDA Advises Investors: How to Read a "Complete Response"
Go to This Issue >>
|
|
|
|
|
 |
 |
 |
|
|
|
A D V E R T I S E M E N T
|
|
|
 |
|
 |
|
|
|
